Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Growing
The company is in a growing phase, with the latest annual income totaling USD 21.05M.
Fairly Valued
The company’s latest PE is -1.73, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 89.88M shares, decreasing 26.83% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 33.31K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.15.